p.k.shah, md director, division of cardiology and atherosclerosis research center
DESCRIPTION
AEHA-AHA-Nov 12-2005, Dallas. “Immunomodulation of Atherosclerosis”. P.K.Shah, MD Director, Division of Cardiology and Atherosclerosis Research Center Cedars Sinai Medical Center, Los Angeles. Vaccine for Atherosclerosis. “Vaccines for infectious diseases - PowerPoint PPT PresentationTRANSCRIPT
P.K.Shah, MDDirector, Division of Cardiology and
Atherosclerosis Research CenterCedars Sinai Medical Center, Los Angeles
““Immunomodulation of Atherosclerosis”Immunomodulation of Atherosclerosis”
AEHA-AHA-Nov 12-2005, Dallas
CSMC--PKS
“Vaccines for infectious diseasesare likely to be the most important medical contribution to public health during the last 100 years -------------”
Nilsson J , Hansson G K , Shah PK: ATVB 2004; 25: 1-11
Vaccine for Atherosclerosis
CSMC--PKS
Yin and the Yang of Immune System in Atherosclerosis
Adaptive ImmunityInnate Immunity
Toll like receptors(TLR) Scavenger Receptors
(SR-A, CD 36)
T-cells B-cells
MacrophagesDendritic Cells
CRPNaturalAntibody
Immune Activation in AtherosclerosisImmune Activation in Atherosclerosis
Auto-antigens Consequences of Immune Response
Hsp-60: Pro-atherogenic 2GP1 : Pro-atherogenic ox-LDL: ???
Both innate and adaptive immune responses modulate atherosclerosis
CSMC--PKS
Apo B100
Cholesterol
LDL cholesterol
Apo B100
Cholesterol
Oxidized LDL
Immune Recognition
B-cells T-cells (antibodies) (cytokines)
PlaqueFormation
Immune Response to Oxidized /MDA-LDL
PhospholipidPhospholipid
Macrophage
Phospholipid Apo B 100Neoantigens Neoantigens
CSMC--PKS
ImmunizedN=9
Immunization of Cholesterol-fed Rabbits with Homologous LDL SubstantiallyImmunization of Cholesterol-fed Rabbits with Homologous LDL SubstantiallyReduces Aortic Atherosclerosis Despite HypercholesterolemiaReduces Aortic Atherosclerosis Despite Hypercholesterolemia
Ext
ent o
f P
laqu
e (m
m2 )
Ameli, Shah, Nillson et al :ATVB 1996Nilsson , Ameli, Shah et al: JACC 1997
Cholesterol 1259mg/dl 1181mg/dl
ControlN=7
Apo B100
Cholesterol
LDL Cholesterol
Apo B100
Cholesterol
Oxidized LDL
Phospholipid Phospholipid
-Antigen: 280 mcg LDL-Adjuvant: 700 mcg AdjuPrime -Primary SC Vaccination followed by 1 booster-Animals euthanzied 16 weeks after vaccination
CSMC--PKS
Palinski , Witztum et al : PNAS 1995
0
10
20
30
40
50
60
70
Control MDA-LDLRabbits Immunized Rabbits(N=11) (N=14)
Immunization of LDL-Receptor Deficient (Watanabe Rabbits) with Homologous Malondialdehyde (MDA) Modified LDL Reduces Atherogenesis
% of Aortic Surface with Plaque
P<0.005
CSMC--PKS
Apo B100
LDL Cholesterol
Cholesterol
302 Peptides, 20 amino acids long with 5 amino acid overlap simulating the entire amino acid sequence of human Apo B 100 were synthesized.
Using an ELISA with peptides sequences as antigens, antibodies to 101 of these peptide sequences were identified in pooled human sera
Several peptide sequences were then used to create vaccines for Immunization in apo E null mice fed a high cholesterol diet
( Collaborative Research Program between Cedars Sinai Medical Center (P.K.Shah) and
University of Lund (Jan Nilsson) )
Hypothesis: Specific antigenic epitopes on Apo B 100 component of LDL provoke athero-protective immune response
Phospholipid
ATVB 2003
Peptide 143 + Peptide 210 Mixture
CSMC--PKS
Immunization of Apo E Null Mice with Apo B-100 related Peptide Sequence Reduces Atherosclerosis
EEEMLENVSLVCPKDATRFK
ATRFKHLRKYTYNYQAQSSS
Peptide 1
Peptide 2
Mouse Apo B 100 Homology
75%
85%
Alum used as adjuvant
6-7 wks 8-9 wks 25 wks
Ist vaccination Booster Sacrifice
CSMC--PKS
Immunization of Apo E Null Mice with Apo B-100 related Peptide Sequence : Effect on Cholesterol Levels and Aortic Atherosclerosis
0
200
400
600
800
1000
1200
1400
1600
Alum(Control)
Peptide 1 Peptide 2
Serum cholesterol mg/dl
Immunization Group
N=9 N=10 N=100
0.5
1
1.5
2
2.5
3
3.5
Alum(Control)
Peptide 1 Peptide 2
% of Aortic Surface Covered by Plaque
Immunization Group
P<0.01
N=9 N=10 N=10
CSMC--PKS
Immunization of Apo E Null Mice with Apo B-100 related Peptide Sequence Reduces Atherosclerosis
CSMC--PKS
Immunization of Apo E Null Mice with Apo B-100 related Peptide Sequence Reduces Plaque Inflammation and Increases Collagen Content
0
2
4
6
8
10
12
14
Alum(Control)
Peptide 1 Peptide 2
% Macrophage immunoreactivity
Immunization Group
p<0.05
N=9 N=10 N=10 0
5
10
15
20
25
30
35
40
45
Alum(Control)
Peptide 1 Peptide 2
% Collagen content (Trichrome)
Immunization Group
p<0.05
N=9 N=10 N=10
Immunization Group:
Late Immunization of Apo E Null Mice with Apo B-100 related Peptide Sequence Attenuates Progression of Atherosclerosis
0
2
4
6
8
10
12
14
Alum Ctl Peptide 2
% Aortic Surface with Plaque
16 wk 30 wk 16 wk 30 wk
Cholesterol (mg/dl): 1274 930 1274 989
P<0.05
CSMC--PKS
0
0.5
1
1.5
2
2.5
3
3.5
Mice receivingSplenocytesFrom AlumImmunized mice
% of Aortic Surface Covered by Plaque
P<0.01
N=9 N=9
Mice receivingSplenocytesFrom Peptide 2Immunized mice
Adoptive Transfer of Splenocytes from Peptide 2 Immunized Mice ReducesAtherosclerosis in Recipient Unimmunized Apo E Null Mice
Mice receivingSplenocytesFrom Peptide 1Immunized mice
N=9
Multiple Apo B-100 Related Peptide Antigens HaveAthero-protective Effects in Apo E Null mice
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
Control Peptide 45 Peptide 74 Peptide210
Peptide240
Peptides11, 25,74
Peptides30-34
Peptides143,210
% Aortic Atherosclerosis Fredrickson, Shah, Nilsson et al : ATVB 2003
CSMC--PKS
Conclusions
Acknowledgements
Kuang-Yuh Chyu , MD, PhD (Cedars Sinai)Xiaoning Li, PhD(Cedars Sinai)Juliana Yano,BS (Cedars-Sinai)
Gunilla Nordin-Fredrickson, MD, PhD (Sweden)Jan Nilsson, MD, PhD (Sweden)
-Immune system plays a complex role in atherosclerosis with pro-atherogenic and athero-protective effects
-Immunization using LDL/ox-LDL and specific Apo B-100 related peptide sequences reduces atherosclerosis and favorably modifies plaque composition
- Immunotherapy of atherosclerosis warrants further investigation
Michael and Jane Eisner Foundation